To extend our results from mouse models to clinical samples, we obtained matched primary breast cancer and brain metastasis samples from six patients with HR+ and/or HER2-amplified breast cancer (average 6.2 years between primary diagnosis and brain metastasis, range: 2.1–15.2 years) (Supplementary Data 4). Here, ERBB2 is linked to breast carcinoma.